SABCS 2022
Camizestrant Improves PFS vs Fulvestrant in ER+/HER2- Advanced Breast Cancer
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Regular users may be at risk for serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy